PDI (PDII +1.3%) says one of its clients has received FDA approval to market its product. PDII...
PDI (PDII +1.3%) says one of its clients has received FDA approval to market its product. PDII will provide an array of promotional services for its rollout, including a dedicated sales team, plus teledetailing and digital communications services. The contract is expected to generate total revenue of approximately $57M over the life of the two-year agreement, with $10M-$11M to be recorded over the second half of 2012.
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs